Codexis

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Codexis reports strong 2022 performance, eyes growth in Life Sciences

Codexis made significant progress in 2022, focusing on high-value programs and enhancing technical capabilities.
While facing challenges in managing expenses and revenue variability, the company is well-positioned with a strong cash position and growth opportunities.
Strategic collaborations and revenue diversification efforts position Codexis for sustainable growth and value creation in the future.

Codexis navigates revenue challenges, eyes growth through strategic partnerships

Codexis is strategically focusing on the ECO Synthesis platform and pharmaceutical manufacturing business for revenue growth and positive cash flow by 2026.
While facing challenges such as impairments on investments and revenue timing, the company is leveraging opportunities through partnerships and operational improvements.
The company's financial discipline, strong balance sheet, and key collaborations position it well for future growth and success in the pharmaceutical manufacturing sector.
With ongoing negotiations and advancements in technology, Codexis is poised for continued progress and innovation in the enzymatic solutions market.

Codexis reports robust Q4 performance, eyes growth through strategic partnerships

Codexis delivered a strong performance in Q4 2023, driven by strategic decisions, partnerships, and financial results showcasing growth potential.
The company's focus on expanding the ECO Synthesis platform and pharmaceutical manufacturing bodes well for sustained revenue growth.
While facing challenges in scaling operations and managing expenses, Codexis is well-positioned to capitalize on market opportunities and drive innovation.

Codexis projects 10% revenue growth, advances in RNA synthesis

Codexis is poised for growth in 2024, with a focus on revenue expansion, product innovation, and strategic partnerships to drive market success.
The company's strong performance in supplying enzymes for various programs underscores its market leadership and technological capabilities.
While facing challenges in diversifying its customer base and sustaining growth, Codexis is leveraging its strengths in technology and innovation to seize emerging opportunities.

Codexis reports Q3 revenue growth, eyes profitability amid strategic investments

Codexis navigates Q3 2024 with revenue growth in pharma manufacturing and strategic investments for future profitability.
Despite a net loss, the company maintains financial stability with a strong cash position and a focus on enhancing capabilities.
Challenges lie in achieving profitability by 2026, managing divestiture impacts, and optimizing gross margins amid operational changes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Codexis, Inc. (CDXS) CEO John Nicols on Q3 2019 Results - Earnings Call Transcript

Big pharma has been slow to innovate and adopt the latest synthetic biology tools, which could vastly speed the creation of new treatments and vaccines. That is, until now, thanks in large part to companies that can engineer proteins to do just about anything we can imagine.

The Medicine Cabinet Of The Future: If You Can Imagine A Drug, This Company Can Make It

Industry and academic leaders convened to discuss the direction of protein engineering for a wide range of applications Industry and academic leaders convened to discuss the direction of protein engineering for a wide range of applications

Codexis’ Protein Engineering Forum Highlights Progress and Future Direction of the Field

REDWOOD CITY, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held at the Intercontinental New York Barclay Hotel.

Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Stitch Fix

Zuora

Your money can buy more shares of these promising companies thanks to an affordable stock price.

3 Top Stocks: Under $20

The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?

Codexis Rolls Into Second Half Armed with Cash

Codexis, Inc. (CDXS) CEO John Nicols on Q2 2019 Results - Earnings Call Transcript

Energy Transfer LP Unit

Hanesbrands

These low-priced shares should be on your radar.

Three Top Stocks Under $20

The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.

Is Codexis a Buy?

The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.

Codexis Bags Novartis as Software Customer, Stays Course in First Quarter

Codexis, Inc. (CDXS) CEO John Nicols on Q1 2019 Results - Earnings Call Transcript

Alphabet

Visa

If you're planning for your kids' future education -- or just looking for great long-term investments -- you may have considered buying shares of a company as a way to generate additional cash in the coming years.

Offset the rising cost of education with these three companies

Investors with a long-term mind-set can look to these three stocks to inject growth into their portfolio.

3 Stocks Poised for Huge Growth Over the Next Decade: Codexis

News for Codexis Stock (CDXS)